Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials. (5th March 2020)

• Record Type: Journal Article
• Authors: Thind, Munveer; Crijns, Harry J.; Naccarelli, Gerald V.; Reiffel, James A.; Corp dit Genti, Valérie; Wieloch, Mattias; Koren, Andrew; Kowey, Peter R.
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 31:Number 5(2020)
• Page Start: 1022
• Page End: 1030
• Publication Date: 2020-03-05
• Subjects: antiarrhythmic drug -- atrial fibrillation -- atrial flutter -- cardioversion -- dronedarone; Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.14405
• Languages: English
• ISSNs: 1045-3873

Abstract

Abstract: Introduction: The phase 3 EURIDIS and ADONIS studies evaluated dronedarone for atrial fibrillation (AF)/atrial flutter (AFL) recurrence in patients with nonpermanent AF. Here we assessed whether patient characteristics and/or treatment outcomes in these studies differed based on the need for cardioversion before randomization. Methods: Time to adjudicated first AF/AFL recurrence, symptomatic recurrence, cardiovascular hospitalization/death, and AF hospitalization, and safety were assessed by cardioversion status. Results: Of 1237 patients randomized (2:1 dronedarone:placebo), 364 required baseline cardioversion (dronedarone 243, placebo 121). Patients requiring cardioversion had a greater prevalence of cardiovascular comorbidities and shorter times to first AF/AFL recurrence compared with those not requiring cardioversion. Dronedarone was associated with longer median time to first AF/AFL recurrence vs placebo regardless of cardioversion status (cardioversion: 50 vs 15 days, hazard ratio [HR] 0.76; 95% confidence interval [CI], 0.59‐0.97; P = .02; non‐cardioversion: 150 vs 77 days, HR 0.76; 95% CI, 0.64‐0.90; P < .01). Dronedarone was similarly associated with prolonged median time to symptomatic recurrence vs placebo in the cardioversion (347 vs 87 days, HR 0.65; 95% CI, 0.49‐0.87) and non‐cardioversion (288 vs 120 days, HR 0.74; 95% CI, 0.62‐0.90) populations. Risk of cardiovascular hospitalization/death and first AF hospitalization was lower with dronedarone vs placebo regardless of cardioversion status, but differences were not statistically significant. The safety of dronedarone was similar in both groups. Conclusion: Patients requiring baseline cardioversion represent a distinct population, having more underlying cardiovascular disease and experiencing a shorter time to AF/AFL recurrences. Dronedarone was associated with improved efficacy vs placebo regardless of cardioversion status.